NovaBay Pharmaceuticals, Inc. (AMEX: NBY) has focused their efforts on developing innovative product candidates that target the treatment or prevention of a broad array of infections in hospital and community environments. Because of the rapid increase in infectious microbes that are resistant to current drugs, many of these infections have become increasingly difficult to treat. Vitro and in vivo tests have proven that the company’s compounds kill a broad range of bacteria, viruses and other infection causing microbes, even those that are resistant to multiple antibiotics. For further information, visit the Company’s web site at www.novabaypharma.com.
- 17 years ago
QualityStocks
NovaBay Pharmaceuticals, Inc. (AMEX: NBY)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – SuperCom Ltd. (NASDAQ: SPCB) Q2 2025 Results Show Record First-Half Profitability, Strong U.S. Contract Wins
SuperCom (NASDAQ: SPCB), a global provider of secured e-Government, IoT, and cybersecurity solutions, reported Q2…
-
QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present at Webull Financial Biotech/MedTech Webinar Series
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharma company developing novel treatments for primary and metastatic cancers…
-
QualityStocksNewsBreaks – FingerMotion Inc. (NASDAQ: FNGR) Showcases Emergency Command Platform at Indonesia Disaster Expo
FingerMotion (NASDAQ: FNGR) announced that its subsidiary, Shanghai JiuGe Information Technology Co., Ltd., is presenting…